Company Immix Biopharma, Inc.

IMMX

US45258H1068

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:33:21 2024-06-10 am EDT			5-day change	1st Jan Change
2.025 ^USD	-0.25%		+3.59%	-70.81%

May. 10	Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation	CI
May. 09	Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Number of employees: 16

Managers	Title	Age	Since
Ilya Rachman CEO	Chief Executive Officer	52	11-12-31
Gabriel Morris DFI	Director of Finance/CFO	38	21-02-28
Graham Ross CTO	Chief Tech/Sci/R&D Officer	64	21-05-31
Nandan Oza PRN	Corporate Officer/Principal	61	17-04-30

Members of the board	Title	Age	Since
Jane Buchan BRD	Director/Board Member	60	21-06-30
Jason Hsu BRD	Director/Board Member	50	12-12-31
Magda Marquet BRD	Director/Board Member	65	21-05-31
Carey Ng BRD	Director/Board Member	45	19-10-31
Helen Adams BRD	Director/Board Member	65	21-05-31
Ilya Rachman CEO	Chief Executive Officer	52	11-12-31
Gabriel Morris DFI	Director of Finance/CFO	38	21-02-28
Yekaterina Chudnovsky BRD	Director/Board Member	39	23-08-21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,486,663	15,438,397 ( 58.29 %)	72,363 ( 0.2732 %)	58.29 %

Name	Equities	%	Valuation
Jason Hsu 18.09 %	4,778,913	18.09 %	10 M $
Yekaterina Chudnovsky 12.27 %	3,241,076	12.27 %	7 M $
AIGH Capital Management LLC 5.887 %	1,555,000	5.887 %	3 M $
Ilya Rachman 4.292 %	1,133,659	4.292 %	2 M $
Carey Ng 3.919 %	1,035,221	3.919 %	2 M $
Bleichroeder LP 3.218 %	850,000	3.218 %	2 M $
Cable Car Capital LLC 2.538 %	670,458	2.538 %	1 M $
Gabriel Morris 2.189 %	578,319	2.189 %	1 M $
Vanguard Group, Inc. (Subfiler) 1.727 %	456,186	1.727 %	962 552 $
Lynwood Capital Management, Inc. 1.533 %	405,000	1.533 %	854 550 $

Immix Biopharma, Inc.

11400 West Olympic Boulevard Suite 200

90064, Los Angeles

http://www.immixbio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.03 USD

Average target price

14 USD

Spread / Average Target

+589.66%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
IMMIX BIOPHARMA, INC.	-70.81%	53.62M
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-13.44%	15.32B
INCYTE CORPORATION	-6.04%	13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B
SWEDISH ORPHAN BIOVITRUM AB	+2.32%	9.06B

Biopharmaceuticals